Viome launches early detection test for oral and throat cancers

By LabPulse.com staff writers

August 4, 2022 -- Viome Life Sciences on Thursday announced the launch of its saliva-based CancerDetect test for oral and throat cancer.

The test leverages mRNA technology and an artificial intelligence platform to detect biomarkers for oral and throat cancer with 95% specificity and 90% sensitivity rates, the firm said.

The technology underlying its test has received U.S. Food and Drug Administration (FDA) breakthrough designation.

According to Viome, its technology leverages a data platform to detect underlying mechanisms for early-stage oral, colorectal, pancreatic, other gastrointestinal, and head and neck cancers.

Viome's screening tool given 'breakthrough device' designation
Viome announced on May 6 its proprietary messenger RNA analysis technology combined with its artificial intelligence platform has been designated a breakthrough...

Copyright © 2022 LabPulse.com

Last Updated mp 8/4/2022 1:00:48 PM